News Gilead buys in vivo cell therapy firm Interius for $350m Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.
Partner Content Partner Content 7th Cell Therapy Analytical Development Summit Join us in fast-tracking the next era of safe, potent, and robust cell therapies to market!
News Galapagos drops plan to split after 'market developments' Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.
R&D For cell therapies, raw material quality hinges on the human... When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.
News Abeona prices rare cell disorder gene therapy at $3.1m Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).
News Alcon claims control of cell therapy firm Aurion Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
